Chronic Hand Eczema Development

Indication definition for Chronic Hand Eczema Development (CHE)

Chronic Hand Eczema development presents a small challenge, due to the fact that we generally observe reduced research activity in this indication. Hand eczema is an inflammation of the skin; the cause is often multi-factorial. Initial management includes avoiding causative irritants or allergens (e.g., by wearing impermeable gloves) and applying emollients and potent topical glucocorticoids.

(Published: PubMed, Tiltle: Hand eczema, Author: Coenraads PJ, Source: N Engl J Med. 2012;367(19):1829.)

Chronic Hand Eczema Development requires you to comprehensively analyze across the synonyms:

  • chronic hand dermatitis (CHD)
  • chronic hand eczema (CHE)
  • hand dermatitis (HD)
  • hand eczema
  • severe hand eczema
  • dyshidrotic eczema

Current treatment

In order to address your Chronic Hand Eczema Development effectively, the current treatment strategies have to be considered.

1st line treatment:  Topical Corticosteroid

Topical corticosteroids are recommended as first line treatment in the management of HE, however continuous long-term treatment beyond 6 weeks only when necessary and under careful medical supervision.

For patients with the severe Chronic Hand Eczema a second line treatment, applying a systemic approach, relative to topical corticosteroids may be required.

2nd line treatment

  • Alitretinoin, an endogenous retinoid related to vitamin A. Studies have shown that oral alitretinoin is effective and well tolerated in the treatment of severe chronic hand eczema.
  • Cyclosporine, a cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed, introduced 1992).

Selected current research

  • Delgocitinib, a janus kinase (JAK) inhibitor, is being developed by Japan Tobacco for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.
  • Asana Biosciences develops an oral janus kinase/SYK inhibitor suppressing inflammation and improves epidermal barrier markers in patients with systemic dermatitis.

Considering your compound for Chronic Hand Eczema development?

Please ask for a Reference Clinical Development Plan (CDP) or contact us under

Reference CDP gives you a head start into your Clinical Development.

intilaris LifeSciences helps you to Plan, Design, and Execute efficient clinical projects.

Chronic Hand Eczema Development
We come from different backgrounds and unite in our passion for creating value and unique experience for our clients.